CD11b is a therapy resistance– and minimal residual disease–specific marker in precursor B-cell...

6
CD11b is a therapy resistance– and minimal residual disease–specific marker in precursor B-cell acute lymphoblastic leukemia by Peter Rhein, Rita Mitlohner, Giuseppe Basso, Giuseppe Gaipa, Michael N. Dworzak, Renate Kirschner-Schwabe, Christian Hagemeier, Martin Stanulla, Martin Schrappe, Wolf-Dieter Ludwig, Leonid Karawajew, and Richard Ratei Blood Volume 115(18):3763-3771 May 6, 2010 ©2010 by American Society of Hematology

Transcript of CD11b is a therapy resistance– and minimal residual disease–specific marker in precursor B-cell...

Page 1: CD11b is a therapy resistance– and minimal residual disease–specific marker in precursor B-cell acute lymphoblastic leukemia by Peter Rhein, Rita Mitlohner,

CD11b is a therapy resistance– and minimal residual disease–specific marker in precursor B-cell acute

lymphoblastic leukemia

by Peter Rhein, Rita Mitlohner, Giuseppe Basso, Giuseppe Gaipa, Michael N. Dworzak, Renate Kirschner-Schwabe, Christian Hagemeier, Martin Stanulla, Martin

Schrappe, Wolf-Dieter Ludwig, Leonid Karawajew, and Richard Ratei

BloodVolume 115(18):3763-3771

May 6, 2010

©2010 by American Society of Hematology

Page 2: CD11b is a therapy resistance– and minimal residual disease–specific marker in precursor B-cell acute lymphoblastic leukemia by Peter Rhein, Rita Mitlohner,

Correlation of CD11b mRNA at diagnosis with percentage of blasts at day 8.

Peter Rhein et al. Blood 2010;115:3763-3771

©2010 by American Society of Hematology

Page 3: CD11b is a therapy resistance– and minimal residual disease–specific marker in precursor B-cell acute lymphoblastic leukemia by Peter Rhein, Rita Mitlohner,

ROC curve analysis of discrimination of FCM-MRD remission status (FCM positive vs negative) and BFM risk stratification (high vs standard) according to CD11b expression levels at

diagnosis.

Peter Rhein et al. Blood 2010;115:3763-3771

©2010 by American Society of Hematology

Page 4: CD11b is a therapy resistance– and minimal residual disease–specific marker in precursor B-cell acute lymphoblastic leukemia by Peter Rhein, Rita Mitlohner,

CD11b protein expression is consistently increased in MRD cells.

Peter Rhein et al. Blood 2010;115:3763-3771

©2010 by American Society of Hematology

Page 5: CD11b is a therapy resistance– and minimal residual disease–specific marker in precursor B-cell acute lymphoblastic leukemia by Peter Rhein, Rita Mitlohner,

CD11b expression in ALL blasts under therapy: modulation vs selection.

Peter Rhein et al. Blood 2010;115:3763-3771

©2010 by American Society of Hematology

Page 6: CD11b is a therapy resistance– and minimal residual disease–specific marker in precursor B-cell acute lymphoblastic leukemia by Peter Rhein, Rita Mitlohner,

CD11b positivity improves discrimination between ALL and normal mature and precursor B cells.

Peter Rhein et al. Blood 2010;115:3763-3771

©2010 by American Society of Hematology


Interleukin-12-Producing CD103+ CD11b− CD8+ Dendritic Cells … · Interleukin-12-Producing CD103 CD11b CD8 Dendritic Cells Are Responsible for Eliciting Gut Intraepithelial Lymphocyte

Interleukin-12-Producing CD103+ CD11b− CD8+ Dendritic Cells … · Interleukin-12-Producing CD103 CD11b CD8 Dendritic Cells Are Responsible for Eliciting Gut Intraepithelial Lymphocyte

8. Acute Lymphoblastic Leukemia

8. Acute Lymphoblastic Leukemia

Irf4-dependent CD103+CD11b+ dendritic cells and the intestinal … · CD103+CD11b+ DCs regulate iNOS expression by small intestinal monocytes and macrophages The expression of iNOS

Irf4-dependent CD103+CD11b+ dendritic cells and the intestinal … · CD103+CD11b+ DCs regulate iNOS expression by small intestinal monocytes and macrophages The expression of iNOS

CD11b Ly6G myeloid cells mediate mechanical inflammatory pain ...

CD11b Ly6G myeloid cells mediate mechanical inflammatory pain ...

Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

Molecular mechanism of leukocidin GH–integrin CD11b/CD18 ...Molecular mechanism of leukocidin GH–integrin CD11b/CD18 recognition and species specificity Nikolina Trstenjaka,1,

Molecular mechanism of leukocidin GH–integrin CD11b/CD18 ...Molecular mechanism of leukocidin GH–integrin CD11b/CD18 recognition and species specificity Nikolina Trstenjaka,1,

CD11b/CD18 (Mac-1) - The Journal of Immunology

CD11b/CD18 (Mac-1) - The Journal of Immunology

NeuN GFAP CD11b

NeuN GFAP CD11b

Acute Lymphoblastic Leukemia.ppt

Acute Lymphoblastic Leukemia.ppt

Pathophysiology of Acute Lymphoblastic Leukemiacdn.intechopen.com/pdfs/44045/InTech-Pathophysiology_of...Pathophysiology of Acute Lymphoblastic Leukemia

Pathophysiology of Acute Lymphoblastic Leukemiacdn.intechopen.com/pdfs/44045/InTech-Pathophysiology_of...Pathophysiology of Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia · Web viewAcute Lymphoblastic Leukemia Title: High Risk B-precursor Acute Lymphoblastic Leukemia. (COG AALL0232) Purpose: To improve the cure rate of

Acute Lymphoblastic Leukemia · Web viewAcute Lymphoblastic Leukemia Title: High Risk B-precursor Acute Lymphoblastic Leukemia. (COG AALL0232) Purpose: To improve the cure rate of

Mycobacterium tuberculosis Infection CD11b Myeloid-Derived ... · for CD11b +highFSC , whereas CD11b lowFSC cells had intermediate Gr1 MFI (Figure 3 A, B). The increased expression

Mycobacterium tuberculosis Infection CD11b Myeloid-Derived ... · for CD11b +highFSC , whereas CD11b lowFSC cells had intermediate Gr1 MFI (Figure 3 A, B). The increased expression

Acute Lymphoblastic Leukemia - ACCC

Acute Lymphoblastic Leukemia - ACCC

Acute Lymphoblastic and Myeloid Leukemia · Acute Lymphoblastic and Myeloid Leukemia Pre- and Post-Disease Form Mary Eapen MD, MS. Acute Lympoblastic Leukemia. Acute Lymphoblastic

Acute Lymphoblastic and Myeloid Leukemia · Acute Lymphoblastic and Myeloid Leukemia Pre- and Post-Disease Form Mary Eapen MD, MS. Acute Lympoblastic Leukemia. Acute Lymphoblastic

Acute Lymphoblastic Leukaemia Lancet 2008

Acute Lymphoblastic Leukaemia Lancet 2008

Acute Lymphoblastic Lymphoma

Acute Lymphoblastic Lymphoma

 · nnb rhein main neckar . nnb rhein main neckar . nnb rhein main neckar

 · nnb rhein main neckar . nnb rhein main neckar . nnb rhein main neckar

Targeted genome editing in acute lymphoblastic leukemia: a ......Keywords: Acute lymphoblastic leukemia, CRISPR-Cas9, Genome editing Background Acute lymphoblastic leukemia (ALL) is

Targeted genome editing in acute lymphoblastic leukemia: a ......Keywords: Acute lymphoblastic leukemia, CRISPR-Cas9, Genome editing Background Acute lymphoblastic leukemia (ALL) is

Acute Lymphoblastic Leukaemia (ALL)

Acute Lymphoblastic Leukaemia (ALL)

Dexamethasone reduces cell surface levels of CD11b on ...

Dexamethasone reduces cell surface levels of CD11b on ...